Skip to main content

Main menu

  • Home
  • About
    • Clinical Chemistry
    • Editorial Board
    • Most Read
    • Most Cited
    • Alerts
    • CE Credits
  • Articles
    • Current Issue
    • Early Release
    • Future Table of Contents
    • Archive
    • Browse by Subject
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
    • Permissions & Reprints
  • Resources
    • AACC Learning Lab
    • Clinical Chemistry Trainee Council
    • Clinical Case Studies
    • Clinical Chemistry Guide to Scientific Writing
    • Clinical Chemistry Guide to Manuscript Review
    • Journal Club
    • Podcasts
    • Q&A
    • Translated Content
  • Abstracts
  • Submit
  • Contact
  • Other Publications
    • The Journal of Applied Laboratory Medicine

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Clinical Chemistry
  • Other Publications
    • The Journal of Applied Laboratory Medicine
  • Subscribe
  • My alerts
  • Log in
Clinical Chemistry

Advanced Search

  • Home
  • About
    • Clinical Chemistry
    • Editorial Board
    • Most Read
    • Most Cited
    • Alerts
    • CE Credits
  • Articles
    • Current Issue
    • Early Release
    • Future Table of Contents
    • Archive
    • Browse by Subject
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
    • Permissions & Reprints
  • Resources
    • AACC Learning Lab
    • Clinical Chemistry Trainee Council
    • Clinical Case Studies
    • Clinical Chemistry Guide to Scientific Writing
    • Clinical Chemistry Guide to Manuscript Review
    • Journal Club
    • Podcasts
    • Q&A
    • Translated Content
  • Abstracts
  • Submit
  • Contact
Review ArticleCitation Classic

Accurate Whole Genome Sequencing as the Ultimate Genetic Test

Radoje Drmanac, Brock A. Peters, George M. Church, Clifford A. Reid, Xun Xu
DOI: 10.1373/clinchem.2014.224907 Published December 2014
Radoje Drmanac
Complete Genomics, Inc., Mountain View, CA; BGI-Shenzhen, Shenzhen, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brock A. Peters
Complete Genomics, Inc., Mountain View, CA; BGI-Shenzhen, Shenzhen, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George M. Church
Department of Genetics, Harvard Medical School, Boston, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifford A. Reid
Complete Genomics, Inc., Mountain View, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xun Xu
BGI-Shenzhen, Shenzhen, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Featured Article: Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG, et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 2010;327:78–81.4

Even 30 years ago, it was obvious that Sanger sequencing had limited throughput, and a more efficient process could replace many tedious gene and genome mapping projects. It would take until the mid-2000s for massively parallel sequencing (MPS)5 technologies to demonstrate they could overtake the Sanger sequencing hegemony. Our paper was not the first description of a viable MPS technology, but it firmly established that human whole genome sequencing (WGS) could be done affordably (<US$5000 in reagent cost), with high accuracy (<1 error in 100 kb), and with high throughput, thus heralding the arrival of personal genome sequencing.

This work was the result of a long effort that started in Serbia in 1987 with a proposal for sequencing by hybridization (SBH) on dot-blot DNA arrays. SBH on random bead microarrays prepared by emulsion PCR, in which a micron-sized bead replaced a millimeter-sized DNA dot, offered a first MPS solution (www.rdrmanac.com). The US Department of Energy and NIST grants funded most of these initial efforts. After the events of September 11, 2001, the NIH received an increase in biodefense funding, and our US$2.3 million grant for ligation-based MPS technology on genomic DNA microarrays was awarded in 2003 by the National Institute of Allergy and Infectious Diseases. These grants and eventually >US$250 million of private and public equity funding resulted in the formation (in 2005) and growth of Complete Genomics, Inc. (CGI), a Silicon Valley company with the audacious goal of sequencing millions of whole human genomes.

Before all these genomes could be sequenced, an efficient technology for arraying and imaging billions of clonally amplified DNA fragments had to be developed. Rolling circle replication in solution was developed to form billions of discrete DNA nanoballs (DNBs), each comprising a concatemer with approximately 500 copies of the original circle. These DNBs were flooded, under optimized conditions, onto silicon chips patterned with densely packed sticky spots resulting in the first DNA nanoarrays for MPS; >90% of 1 billion spots were occupied by 1 DNB without overcrowding the array. These simple-to-prepare patterned DNA arrays provided low-volume (low-cost) sequencing reactions and efficient imaging by use of fewer camera pixels per spot. Building on our prior work, we further developed a low-cost ligation-based sequencing method that did not require engineered enzymes or cleaving labeled probes. A sophisticated mate-pair library with 4 synthetic adapters inserted into each circular DNB template allowed us to read up to 70 discontinuous bases per DNB. Analyzing the data required development of special statistical algorithms and software, including local de novo sequence assembly, to call all types of variants, including single-nucleotide variants, indels, structural variants, and copy number variants. The combination of these advanced algorithms, affordable high read coverage, and inherently unbiased sequencing chemistry resulted in the first demonstration of human WGS that had an error rate <1 in 100 kb. This established that short mate-pair reads could provide high-quality human WGS. We further refined this technology to take advantage of patterned DNB arrays by creating nanoarrays with 3–4 DNBs per square micrometer and achieving the ultimate imaging efficiency of a single pixel per DNA spot (1). These improvements allowed CGI to establish a human WGS service capable of analyzing >1000 samples per month at 50× read coverage.

Twenty thousand human genomes later, the payoffs from our MPS technology are becoming clear through hundreds of studies demonstrating the power of high quality WGS and advancing the understanding of the genetics behind many diseases. Some of the early success stories with our technology include the first demonstration that WGS in a nuclear family could determine the genetic underpinnings of mendelian disorders (2) and furthering the understanding of what causes cancer (3, 4). The most recent landmark study that used CGI WGS technology demonstrated that causative de novo mutations can be detected in >60% of children with intellectual disabilities (5). Our WGS service has also participated in a number of population studies such as 1000 Genomes, the Wellderly Study, and the Personal Genome Project (www.personalgenomes.org), as well as sequencing and making freely available the whole genomes of 69 commonly studied cell lines (www.completegenomics.com/public-data/69-Genomes/).

In addition, our efficient WGS has enabled long fragment read technology, a process for highly accurate WGS (1 error in 10 Mb) and haplotyping from 10 cells (1). This process makes possible the use of individual WGS as the ultimate genetic test (6), as well as accurate WGS from samples in which only a small number of cells are available (e.g., microbiopsies). In molecular diagnostics, our MPS is the first next generation sequencing test in the world approved by a government agency. BGI, a genomics company that recently acquired CGI, registered a noninvasive prenatal test with China's Food and Drug Administration on the basis of a modified CGI sequencing platform.

This is not the end of the story for MPS and patterned DNA arrays. Advances in imaging, 2-color base labeling, and other improvements in sequencing chemistry, combined with our patterned DNB nanoarrays and large-scale manufacturing through BGI, have the potential to achieve dramatic cost reduction toward $1 per gigabase of raw reads in the next few years. This level of efficiency, coupled with advanced computing, will enable, on a global scale, the highest-quality individual WGS tests as well as cancer WGS, transcriptome, metagenome, and other omics analyses performed as routine checkups. Ultimately, these widespread analyses will be used for both understanding the genetic basis of disease and implementing personalized disease prevention and treatment through genomic medicine.

Footnotes

  • ↵5 Nonstandard abbreviations:

    MPS,
    massively parallel sequencing;
    WGS,
    whole genome sequencing;
    SBH,
    sequencing by hybridization;
    CGI,
    Complete Genomics, Inc.;
    DNB,
    DNA nanoball.

  • ↵4 This article has been cited more than 530 times since publication.

  • Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

  • Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

  • Employment or Leadership: R. Drmanac, Complete Genomics, Inc.; B.A. Peters, Complete Genomics, Inc.; C.A. Reid, Complete Genomics, Inc.

  • Consultant or Advisory Role: G.M. Church, CGI Scientific Advisory Board.

  • Stock Ownership: R. Drmanac, BGI; B.A. Peters, BGI (the parent company of Complete Genomics, Inc.); C.A. Reid, BGI; X. Xu, BGI.

  • Honoraria: None declared.

  • Research Funding: None declared.

  • Expert Testimony: None declared.

  • Patents: Rdrmanac, patent nos. 8785127 and 8763375; B.A. Peters, patent no. 8592150 B2.

  • Other Remuneration: G.M. Church, see http://arep.med.harvard.edu/gmc/tech.html.

  • Received for publication October 24, 2014.
  • Accepted for publication October 28, 2014.
  • © 2014 American Association for Clinical Chemistry

References

  1. 1.↵
    1. Peters BA,
    2. Kermani BG,
    3. Sparks AB,
    4. Alferov O,
    5. Hong P,
    6. Alexeev A,
    7. et al
    . Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. Nature 2012;487:190–5.
    OpenUrlCrossRefPubMed Order article via Infotrieve
  2. 2.↵
    1. Roach JC,
    2. Glusman G,
    3. Smit AF,
    4. Huff CD,
    5. Hubley R,
    6. Shannon PT,
    7. et al
    . Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 2010;328:636–9.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Lee W,
    2. Jiang Z,
    3. Liu J,
    4. Haverty PM,
    5. Guan Y,
    6. Stinson J,
    7. et al
    . The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010;465:473–7.
    OpenUrlCrossRefPubMed Order article via Infotrieve
  4. 4.↵
    1. Molenaar JJ,
    2. Koster J,
    3. Zwijnenburg DA,
    4. van Sluis P,
    5. Valentijn LJ,
    6. van der Ploeg I,
    7. et al
    . Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012;483:589–93.
    OpenUrlCrossRefPubMed Order article via Infotrieve
  5. 5.↵
    1. Gilissen C,
    2. Hehir-Kwa JY,
    3. Thung DT,
    4. van de Vorst M,
    5. van Bon BWM,
    6. Willemsen MH,
    7. et al
    . Genome sequencing identifies major causes of severe intellectual disability. Nature 2014;511:344–7.
    OpenUrlCrossRefPubMed Order article via Infotrieve
  6. 6.↵
    1. Drmanac R
    . The ultimate genetic test. Science 2012;336:1110–2.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Clinical Chemistry: 61 (1)
Vol. 61, Issue 1
January 2015
  • Table of Contents
  • About the Cover
  • Index by author
  • Table of Contents (PDF)
  • Cover (PDF)
  • Advertising (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
  • Audio summary of this issue
Print
Share
Accurate Whole Genome Sequencing as the Ultimate Genetic Test
Radoje Drmanac, Brock A. Peters, George M. Church, Clifford A. Reid, Xun Xu
Clinical Chemistry Jan 2015, 61 (1) 305-306; DOI: 10.1373/clinchem.2014.224907
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Accurate Whole Genome Sequencing as the Ultimate Genetic Test
Radoje Drmanac, Brock A. Peters, George M. Church, Clifford A. Reid, Xun Xu
Clinical Chemistry Jan 2015, 61 (1) 305-306; DOI: 10.1373/clinchem.2014.224907

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Circulating microRNAs: In a Class of Their Own
  • Technology Meets Opportunity: High-Sensitivity Troponin Testing for Screening Apparently Healthy Adults
  • Measurement of Treatment Effects Require Instruments Responsive to Change Based on the Minimal Important Difference
Show more Citation Classic

Similar Articles

Subjects

  • SUBJECT AREAS
    • Other Areas of Clinical Chemistry
  • SECTIONS
    • Citation Classics

Options

  • Home
  • About
  • Articles
  • Information for Authors
  • Resources
  • Abstracts
  • Submit
  • Contact
  • RSS

Other Publications

  • The Journal of Applied Laboratory Medicine
Footer logo

© 2019 American Association for Clinical Chemistry

Powered by HighWire